Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
暂无分享,去创建一个
M. Kanda | T. Yoshikawa | J. Sakamoto | S. Saji | K. Oba | K. Kashiwabara | C. Hamada | S. Mayanagi | S. Sadahiro | M. Honda | T. Aoyama | H. Maeda
[1] D. Sargent,et al. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Yoshikawa,et al. Hazard rate of tumor recurrence over time: A pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese foundation for multidisciplinary treatment of cancer (JFMC) , 2016 .
[3] K. Sugihara,et al. Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies , 2016, Expert opinion on pharmacotherapy.
[4] Y. Kakeji,et al. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] S. Hendren,et al. Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. , 2015, Diseases of the colon and rectum.
[6] Nobhojit Roy,et al. The Global Burden of Cancer 2013. , 2015, JAMA oncology.
[7] S. Kitano,et al. Short-Term Surgical Outcomes From a Randomized Controlled Trial to Evaluate Laparoscopic and Open D3 Dissection for Stage II/III Colon Cancer: Japan Clinical Oncology Group Study JCOG 0404 , 2014, Annals of surgery.
[8] N. Tomita,et al. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial) , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] F. Lordick,et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Meyerhardt,et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Parks,et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.
[12] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] C. Lepage,et al. Prevalence of patients with colorectal cancer requiring follow-up or active treatment. , 2009, European journal of cancer.
[14] Mithat Gonen,et al. Individualized prediction of colon cancer recurrence using a nomogram. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Xiaomei Ma,et al. Global Burden of Cancer , 2006, The Yale journal of biology and medicine.
[16] Y. Ohashi,et al. Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil , 2006, Langenbeck's Archives of Surgery.
[17] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Buyse,et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Yasutomi,et al. Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer , 1998, International Journal of Clinical Oncology.
[20] Y. Ohashi,et al. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur , 2004, International Journal of Clinical Oncology.